Patients with PIK3CA-altered advanced cancer were treated with the p110α selective inhibitor Alpelisib (BYL719) and one patient with endometrial cancer showed a complete response and another showed a partial response to treatment ([116], NCT01219699). The gene discussed is PIK3CA; the disease is endometrial cancer.